COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03349450
Recruitment Status : Recruiting
First Posted : November 21, 2017
Last Update Posted : July 24, 2019
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2021